New Long-Acting HIV combo shot aims to simplify treatment

NCT ID NCT07402044

Not yet recruiting Disease control Sponsor: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a long-acting combination of two HIV drugs (cabotegravir and lenacapavir) works in 50 adults with HIV-1. Participants either already take this treatment or will start it by doctor's order. The main goal is to see if the virus stays suppressed (below 50 copies/mL) and to monitor side effects and immune changes over one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CABOTEGRAVIR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CABOTEGRAVIR LENACAPAVIR

Contacts and locations

Locations

Archet 1Hospital

Nice, France
Bichat Claude Bernard Hospital

Paris, France
Franco-British Hospital (Fbh)

Levallois-Perret, France
Hotel Dieu Hospital

Nantes, France
Hotel Dieu Hospital

Paris, France
Necker Hospital

Paris, France
Pellegrin Hospital

Bordeaux, France
Pitié Salpêtrière Hospital

Paris, France
Raymond poincaré Hospital

Garches, France
Saint André Hospital

Bordeaux, France
Saint Antoine Hospital

Paris, France
Tourcoing Hospital

Tourcoing, France
Victor Dupuy Hospital

Argenteuil, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.